In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), with a price target of $8.00. The company’s shares opened today at $1.87.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Nkarta, and Gracell Biotechnologies. According to TipRanks, Bodnar has an average return of -7.3% and a 33.33% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IO Biotech with a $10.33 average price target.
See the top stocks recommended by analysts >>
Based on IO Biotech’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.04 million. In comparison, last year the company had a GAAP net loss of $17.2 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Read More on IOBT:
- IO Biotech Announces 2023 Second Quarter Results
- IO Biotech Appoints Heidi Hunter to its Board of Directors
- IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
- IO Biotech to sell 37.07M shares at $2.025 in private placement
- IO Biotech, Inc. Announces $75 Million Private Placement Financing
